Topical therapy of nail diseases by Murdan, S
When working in industry, it mightbe difficult to imagine how many
government-related employees spend
a large proportion of their everyday job
discussing how best to support your
business.  If you have attended a con-
ference organised by LTN, for example,
you will probably not be aware that we
are taking every creative measure to
ensure that you will get the most out
of your day, and we cross our fingers
behind our backs for you when we see
you talking with potential collaborators
over a glass of wine.  When you tell us
that you have spent half a day dis-
cussing a project with somebody we in-
troduced you to, we get very excited in
our office.  If you then launch into a
collaborative partnership, be it signing
a material transfer agreement or a
submission of a joint grant proposal,
we go out for a pint on your behalf as
the news absolutely makes our day (as
sad as it may sound). 
Governments, of course, aim to foster
an array of vibrant industries in their
countries and invest an extortionate
amount of resources in laying out the
optimum policies and systems at all
levels. At LTN (funded by the regional
development agencies and the Euro-
pean Commission) we aim to do this on
the ground level, focussing on sup-
porting research-intensive industries
in all sectors. Our core activities are in
promoting collaborative projects be-
tween industry and academia, as well
as business to business.
On Tuesday last week, I found myself
representing London and the South
East of England in a bi-annual meeting
of the Biotech & Pharma Sector Group
of the pan-European technology
transfer network Enterprise Europe
Network (EEN), of which, as you know,
LTN is a partner in two consortia. The
network is funded for by the European
Commission and is the largest of its
kind in the world; it is made up of 600
local contact points employing a total
of nearly 3,000 experienced staff
spread around Europe. 
As the least European-looking member
of this Sector Group, I sat there 
discussing how we could promote in-
ternationalisation for biotech and
pharma companies in our own regions.
The immediate and obvious strategy
has always been to organise interna-
tional brokerage events and trade
shows. It is becoming increasingly obvi-
ous to us, however, that these interna-
tional conferences don’t yield the
proportional amount of successful
outcomes (ie, international partner-
ships signed) considering the amount
of resource that goes into their or-
ganisation. How can we add more value
and distinguish ourselves from giant
commercial conferences such as BIO
and BioPartnering Europe? Should we
be competing with these conferences
anyway?   
There is something to be said about
small bilateral “missions” of a handful
of invited companies in a particular
field, say regenerative medicine, com-
ing over from (say) France for a tar-
geted networking and partnering
meeting with around 50 UK delegates.
Such missions are frequently organ-
Welcome to the latest issue of the EMT newsletter. This issue covers a review of our recent networking event which we organised around the Technology Strategy Board competition on
fighting infection through detection. Two posters presented at this meeting have been hand-picked
and are included on page 6.  We introduce Stabilitech, a private company in London that allows for the
stable storage of vaccines, and we also have an article on topical delivery of nail therapies from Dr
Sudax Murdan at the School of Pharmacy, University of London.  
Our upcoming conference Biomarker Discovery and Validation takes place on 28 April and I am
pleased to say that we are already seeing an excellent number of companies registering. We are also
working with the Oxford Biotechnology Network to run a technology showcase at the BioTrinity 
conference on 14 April in Oxford.  
We hope you enjoy this issue and look forward to seeing you soon.
- Maki Aoyama, Business Development Manager, Life Sciences, LTN
medisphere
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Neither the European Commission nor the Executive Agency for Competitiveness and Innovation nor any person acting on behalf of them is responsible for the use which might be made of the information contained
herein. The views in this publication are those of the author and do not necessarily reflect the policies of the European Commission.
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Upcoming 
External Events
BioEurope
8-10 March, 2010
Barcelona, Spain
www.ebdgroup.com/bes
eHealth Conference
15 March 2010
Barcelona, Spain
www.ehealthweek2010.org
Medical Innovation 2010
17-18 March 2010
University of Oxford, UK
www.sbs.ox.ac.uk
Repairing the Body
22-23 April 2010
Cranfield University, UK
www.repairingthebody.com
Chemical Biology Centre & Rasor:
Joint Technology Showcase Event
30 June 2010
www.imperial.ac.uk/
chemicalbiologycentre/tsc2010
To submit your event to the EMT
website email Natalie at 
N.Tamiollo@LTNetwork.org.
Upcoming
LTN Events
BioTrinity 
Technology 
Showcase
14 April 2010
Oxford, UK
Biomarkers 
Discovery and Validation
28 April 2010
London, UK
LTN events have restricted access.
To learn more phone 0870 730 8661
or email Lauren at 
L.Gold@LTNetwork.org 
Sectors
continued
The 2011Health Call
work pro-
gramme will
be published
in July 2010
for proposals
to be selected in 2011. This year a sig-
nificant emphasis has been placed on
SME involvement, with a set of “SME
friendly” topics  that allow greater flex-
ibility of  research area and mandate
that up to 50% of the allocated funding
goes to SME partners. Many other top-
ics require at least one SME partner
and a high proportion use the two stage
evaluation process to reduce the initial
risks. Selected topic areas include
genome-based biomarkers, regenera-
tive medicine and microbial resistance,
all with an emphasis on more applied as-
pects. Other notable features are the
appearance of specific Clinical Trials
topics across a range of disease types,
again with encouragement for SME
participation, a wide range of topics re-
quiring international co-operation and
two pilot High Impact projects with
budgets of up to  30 million that will lead
to integrated research programs in
epigenomics  and immunisation strate-
gies.   
Though the work programme is not yet
available for public distribution it is an-
ticipated that the full draft version will
be agreed in the March-April time-
frame. Look out for further information
and announcements on the FP7UK web-
site www.FP7uk.co.uk  or contact Gra-
ham Hughes, the Health Theme National
Contact Point responsible for SMEs,
through the central FP7UK helpline
help@fp7uk.co.uk. Local support is also
available through the Enterprise Europe
Network.
ised by UKTI and foreign embassies,
some of which LTN has in the past co-
organised. I have also in my separate ca-
pacity run the first Japan Biotech
Forum in London last September, and
was pleasantly surprised with the par-
ticipation of a good number of European
pharma and the number of meetings
they requested with the invited Japan-
ese biotech companies. “Targeted” and
“personalised” are key words for us in
planning our future activities. As such I
have offered at the EEN Sector Group
meeting, that LTN can host such a bilat-
eral mission within the year ahead, re-
sulting in a number of nods of approval
from members representing biotech
clusters around Europe - so do watch
this space.
You may have also noticed that we are
now proactively assisting companies find
partners for joint grant applications and
bid submissions. Although we can do little
in terms of helping companies raise
money from private sources such as
business angels and venture capitalists,
we can certainly advise companies on ac-
cessing public funds and forming con-
sortia that would strengthen their
chances of winning bids, thereby lever-
aging their R&D spend. 
You will see that my colleague Jolyon
White has written a review about a re-
cent conference we organised sur-
rounding the latest Technology Strategy
Board competition in the area of infec-
tious disease diagnostics. We are start-
ing to receive feedback on the outcomes
of our support, such as the number of
partnerships formed surrounding this
competition and beyond. It would be ex-
tremely interesting to us to see how
much our clients have been rewarded as
a result, and how much value this would
add to their projects and eventually
product lines - this may certainly result
in a series of pub outings for us!
- Maki Aoyama 
Business Development Manager,
Life Sciences, LTN
2011 FP7 
Health call
from page 1
A
s those of you who attend LTN
events will know - it depends on a
combination of marketing to get the
right audience mix, then partnering
and networking, not to mention a lot of
prior communication with the dele-
gates on the mix of organisations.
These activities require the heavy use
of the LTN’s CRM database and a num-
ber of other server based pro-
grammes. But electricity shortages in
early January left the LTN offices
closed for three days and in addition
the weather worsened and it was
looking like any delegates coming from
more than a few miles away would not
be able to make it in. The event went
ahead and LTN thanks its supporters
for making some fantastic efforts to
attend. The forecast was far from op-
timistic, however delegates came
from all over the country by a variety
of means. Several made emergency
contingency arrangements to stop
overnight. As far as we know only one
was stopped - being trapped
overnight at an airport.
Fighting Infection through Detection
was particularly important in the cur-
rent economic climate. For some time
now, LTN has been working with the
LDA and the TSB to assist companies
and public sector research centres
come together in consortia in order
to bid for TSB R&D support. The event
was designed to on the one hand ex-
plain the criteria and mechanisms for
obtaining TSB support and on the
other, to explore the issues around
working in consortia.
The event opened with a succinct in-
troduction from LTN’s Maki Aoyama
and proceeded with presentations
from Penny Wilson and Sue Dunkerton
for the TSB. Penny and Sue are key fig-
ures in the TSB’s Infectious Disease
Diagnostics Programme. This pro-
gramme has been joined by the De-
partment of Health and DEFRA and is
aimed at the rapid detection of a num-
ber of human and animal diseases (see
table 1.)
These are familiar targets where late
detection leads to increased levels of
morbidity, mortality and economic
cost. 
The next two speakers addressed the
issues of working in consortia towards
a common goal. 
It is often overlooked that the typical
tensions of managing a project are
magnified when this is across organi-
sational boundaries. Lines of commu-
nication are often unclear, availability
of resource is less predictable and au-
thority is sometimes not obvious. The
skills of the project manager in these
circumstances are of paramount im-
portance and their job is made all the
more difficult by the often ignored
cultural differences between the or-
ganisations in the consortia.
Both Dr Roger Rosedale and Profes-
sor Phillip Butcher brought out these
issues and the importance of ad-
dressing them at the outset, illus-
trating these points with case
studies of both successful and less
successful projects.
Dr Rosedale concluded that it is im-
portant to consider the strategic im-
portance and fit of the project to all
the partners in the consortia and to
ensure that this was not missed be-
hind the bright light of low cost fi-
nance for the research programme.
There is a real risk that the benefits
of the leverage will be lost if the con-
sortia objectives are not clear and
aligned. Furthermore a failed project
in these circumstances can lead to
considerable loss of reputation and
credibility.
Conversely both speakers concluded
that with the right mix, alignment of
objectives and competent project
management, consortia can reap
enormous benefit from collaborative
R&D.
- Jolyon White,
Technology Consultant,
Life Sciences, LTN
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Fighting Infection Through
Detection: Event Review
LTN’S JOLYON WHITE EXPLORES THE SUCCESSES OF A RECENT LTN EVENT.
Human Animal
• Tuberculosis
• Sepsis
•Antimicrobial 
resistance to: 
MRSA
C. difficile
ESBL producing
bacteria
Community ac-
quired pneumonia
Antibiotic 
prescribing
• STD:
Chlamydia
Gonorrhoea
• FMD
• Swine Vesicular
• M. bovis
• Bluetongue
• Classical swine
fever
• African swine
fever
• Avian influenza 
(H5 and H7)
Table 1. The priority areas for the Detection and 
Identification of Infectious Agents Innovation 
Platform
LTN tweets and links
LTN is now on Twitter as Ltechnetwork and join the Linkedin group LTN Events to 
discuss future topics and have your say in determining upcoming event topics  
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The nail plate - commonly referred toas ‘the nail’ - is the most obvious
part of the nail unit, which also includes
the nail matrix (the ‘root’ which pro-
duces the plate), the nail folds (the skin
surrounding the nail plate), the hypony-
chium (the tissue underneath the nail
plate at the tip of the digit) and the
nail bed (the tissue underlying the nail
plate), as shown in the Figure. A re-
markably wide range of afflictions can
affect the nail plate and alter its size,
shape, colour, mechanical strength,
growth rate, attachment to the un-
derlying tissue, as well as cause inflam-
mation of the skin surrounding the nail.
While some of these symptoms, such
as white spots on the nail plate, only
pose minor cosmetic concerns, others
cause considerable pain and distress
(e.g. infections) or can be symptoms of
more serious, internal disease (e.g. nail
clubbing). 
Topical therapy of nail diseases, where
appropriate, would be ideal to target
drugs to their site of action and avoid
the side effects and drug interactions
associated with systemic drug expo-
sure.  However, the poor permeability
of the nail plate limits ungual drug flux,
and thence the success of topical
therapy.  Consequently, few topical nail
medicines are currently available, and
these are mainly for the treatment of
fungal infections -the most common
nail disorder.  Nail varnish containing an
antifungal agent e.g. Curanail (also
called Loceryl®, containing the antifun-
gal amorolfine) and Penlac® (containing
ciclopirox) have the advantage of
longevity on the nail over the older for-
mulations, Trosyl® (a solution contain-
ing the antifungal tioconazole) and
Phytex® (a paint containing the fungi-
cidal boric acid, tan-
nic acid), which have
to be applied twice a day, being easily
removed during normal daily activities
such as washing.  All the formulations
however have to be applied for long
durations - up to one year.  
In an attempt to improve topical ther-
apy, the nail plate and especially its
permeability is the subject of much re-
search.  Potential physical and chemi-
cal drug delivery enhancers, such as
electricity, ultrasound, lasers, acids and
other keratin-disrupting chemicals,
are being identified.  The nail varnish
remains a popular choice as a drug
carrier, although other formulations,
such as patches and films, are also
under investigation, as are new drugs
designed specifically for topical deliv-
ery.  The research should lead to more
effective topical nail medicines, not
only for fungal infections, but also for
other nail diseases such as psoriasis.
Dr Sudaxshina Murdan, The School of
Pharmacy, University of London. 29-39
Brunswick Square, London.  S Murdan’s
research includes topical drug delivery
to the nail. Tel: +44-2077535810, email:
sudax.murdan@pharmacy.ac.uk 
Topical therapy of nail diseases 
Newsletter Feedback!
We are constantly seeking to improve our news services. We would therefore be very grateful ifyou could spare a few minutes to complete a short online questionnaire about “Medisphere”,
which you have subscribed to. This will help us to improve this service. All answers will be handled in
strictest confidence. Visit http://tinyurl.com/ltnemtsurvey.
Detection & diagnosis event
The Infectious Disease ResearchNetwork and the Health Protection
Agency are collaborating on a one-day
workshop entitled Applications of
Point of Care tests to infectious dis-
ease detection and diagnosis. The
event will be held on 14 May 2010 at the
National Space Centre, Leicester. 
The workshop will discuss research
priorities in the area of infectious dis-
ease diagnostics, including topics such
as the development of
diagnostic/triage devices with regards
to infectious disease diagnosis, and
the development of point of care tests
for diagnosis of GI infections, STIs and
blood borne viruses. 
There is also the opportunity to submit
abstracts for a poster presentation. 
Speakers include representatives
from: Technology Strategy Board, Uni-
versity of Leicester, Ministry of De-
fence, University of Bristol, University
of Cambridge. To learn more and regis-
ter visit: http://idrn.org/events/up-
coming/diagnostics.php  
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Novel odour analysis device
Testing has begun on a device thatcan sniff out the presence of dis-
ease by smell, thanks to a £1.3 million
Translation Award from the Wellcome
Trust. OdoReader, developed by Chris
Probert from the University of Bristol
and Norman Ratcliffe from the Univer-
sity of the West of England, uses pio-
neering technology to rapidly diagnose
Clostridium difficile, by ‘reading’ the
odour of stool samples. Clostridium
difficile can cause severe diarrhoea,
especially among hospitalised patients.
With the help of University Hospitals
Bristol NHS Foundation Trust, the
technology enables gases emitted
from faeces to be analysed in under an
hour, leading to a rapid and inexpensive
diagnosis. Such early detection could
reap real health benefits for millions of
people and help to prevent the spread
of infectious disease.
The Wellcome Trust Translation Award
will cover a three-year programme of
work to support the development of
OdoReader proto-
types, which will
then be tested
against the industry
‘gold standard’
method of making the diagnosis. 
Rick Davis, Business Development
Manager at the Wellcome Trust, said:
“Wellcome Trust Translation Awards
are designed to facilitate the develop-
ment and commercialisation of new
healthcare technologies. OdoReader
has shown great promise in early test-
ing and we are hopeful that this diag-
nostic platform will prove valuable in
the race against ‘superbugs’.”
Researchers from both academic insti-
tutions and early-stage companies are
eligible to apply for a Wellcome Trust
Translation Award. The awards aim to
support applied research and develop-
ment projects that address an unmet
need in healthcare. Funding is available
for projects from the following areas:
diagnostics, enabling technology, regen-
erative medicine, therapeutics, vac-
cines and medical devices. 
The deadline for preliminary applica-
tions is 23 July. For more information
visit www.wellcome.ac.uk/techtrans-
fer/emt
Stabilitech’s core technology allowsthe stable storage of vaccines and
other biological molecules at ambient
temperature, removing the need for
refrigeration. Inspiration for the tech-
nology came from nature, which has
already solved the challenge of sta-
bilising complex biological materials
against thermal and desiccation
stress, as for example in seeds, which
can be stored under hot and dry con-
ditions for extended periods of time,
but still germinate successfully. 
Stabilitech’s approach mimics some
aspects of these natural principles
and uses entirely chemical excipients
which are inexpensive, readily available
and have already been previously used
in a clinical setting. The process can be
readily integrated into existing cGMP
manufacturing processes and involves
freeze-drying using standard equip-
ment.
Stabilitech technology has been shown
to be successful in the stabilisation of
a wide range of live viruses, both for
enveloped viruses such as the ther-
mally fragile measles virus, and non-
enveloped viruses such as adenovirus,
as well as inactivated viruses and sub-
unit vaccines. For example, the figure
shows an extremely high level of ac-
tive-virus retention in the presence of
our excipients, even after treatment
of measles virus at 37°C for almost a
week in a freeze-dried state. This is in
contrast to the complete loss of virus
activity in the absence of excipients
under the same conditions. Stabilitech
technology clearly has the potential
for use in both human and animal
vaccines. 
Stabilisation of proteins and other
unstable biological molecules has
also been successfully achieved. So
far, Stabilitech has stabilised specific
antibodies, enzymes, peptides and
other proteins such as growth fac-
tors. 
- Stephen Ward,
Director of Development,
Stabilitech Ltd
Stabilitech is a private company based in Lon-
don, in the Imperial College Incubator provid-
ing stabilization solutions to the vaccine and
biopharma community.
Stable storage of vaccines
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LTN infection posters
LTN REPRINTS TWO POSTERS FROM OUR JANUARY EVENT: 
FIGHTING INFECTION THROUGH DETECTION
February 2010    Page 7
Online technology profiles from 
Enterprise Europe Network
The following profiles are examples of the latest innovations available online now, at www.LTNetwork.org/services/tech-search.asp, as part of Enterprise Europe Network
(a free service of which LTN is a key partner). If you’re seeking new technologies, would like to
market your own innovations to Europe, or would like to learn more about the profiles below, then email the name and
profile number to Maki Aoyama at m.aoyama@LTNetwork.org. 
Title Description Country Type
New drug for prevention and
treatment of Parkinson and
related diseases (10 ES 24D8
3G7K)
A Spanish university has developed a new drug based on 3-phenyl-6-
substituted coumarins' preparation that can be used as a powerful and 
selective inhibitor of monoamine oxidases (MAO). The prepared compound is
much more active and selective inhibitor of MAO-B than selegiline, a drug used
clinically for treating of Parkinson disease. Its easy preparation from inexpen-
sive starting materials suggests a good development for commercial use.
Spain Offer
Smart Prostheses - Electro
Mechanic Systems for 
Prostheses Equipment (09 TR
98OA 3G1C)
Turkish company specialized on production of prosthesis products for medical
industry is searching for technology, product and partner company to develop
innovative prostheses products. It needs technologies for electro mechanic
systems for prothesis equipment. 
Turkey Request
Special new adjustable, tiltable
wheelchair and seating (10 HU
50S5 3GBE)
A Hungarian technology-transfer agency offers a new adjustable, tiltable
wheelchair and seating designed and developed by a team composed of 
hospitals, distributors, college professors, and disabled persons' associations.
This new wheelchair is repairable and cheaper than the others in the market. 
Hungary Offer
Technology to stick miniature
metal parts for production of
miniature hearing aids being
sought (09 PL 63AW 3G25)
Polish company is looking for a solution to stick miniature metal parts used for
production of miniature hearing aids. An alternative technology to laser bind-
ing and gluing is sought. The requested technology is to be used for the pro-
duction of elecromechanical advanced solutions and miniature components.
Requested technology can either be at the laboratory stage or fully developed.
Poland Request
New pharmaceutical molecule
with kynurenic acid to treat
gastrointestinal disorders (10
HU 50S5 3GB1)
A Hungarian medical research institute, active in the field of the kynurenic acid
research, has developed a molecule with highly protective effects on the 
gastrointestinal system. Pharmacological values, effects of the molecule could
be interesting for the pharmacological industry. 
Hungary Offer
Regional Registry of new borns
with congenital malformations
for implementing new methods
of prevention and treatment.
(10 RO 75DV 3G8W)
A Romanian company is looking for an innovative database to register new
borns with congenital malformations for implementing new methods of 
prevention and treatment. Technology requested can either be at developing
stage or fully developed. Preferred type of collaboration is commercial and/or
subcontracting agreement.
Romania Request
Pharmaceutical composition
and pharmaceutical kit for the
treatment of Hepatocellular
Carcinoma (10 IT 54V8 3G3Z)
An Italian University research laboratory has developed an invention, in which
the expression of Notch receptors in human tissue samples of Hepatocellular
Carcinoma (HCC) and adjacent HCC-free tissue has been explored. This inven-
tion can be very useful in the treatment of HCC, which ranks fifth in frequency
worldwide among all human cancer and causes 1 million deaths annually.
Italy Offer
Technology for modeling and
simulating human behavior in
light of diminishing behavioral
disorders (Ref: 10 RO 75DV
3G8T)
A romanian company is looking for an innovative solution for modeling and 
simulating human behavior in light of diminishing behavioral disorders. The
technology requested can either be at developing stage or fully developed.
Preferred type of collaboration is commercial and/or subcontracting 
agreement.
Romania Request
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Title Description Country Type
Improved Orthopedic Device
(10 IT 54V8 3G3X)
An Italian University research laboratory has developed designs of internal
knee prosthesis. These designs allow the replication of the relative motion 
between tibia and femur quite well since they rely upon mechanical guided 
connections between them instead of the residual anatomical structures
(such as ligaments, muscles, soft tissue) after the surgical implantation of the
prosthesis, like most of the existing prostheses do. 
Italy Offer
Innovative technologies for
agro-food and biopharmaceu-
tical production (09 IT 53U9
3FS0)
An Italian company supplying molecular biology services, with expertise in the
development of engineered enzymes for fine chemicals, agro-food and 
biopharmaceutical production, is looking for new devices, methods, ingredients
or additives useful for agro-food or pharmaceutical or nutraceutical 
industries to obtain new products. The company is interested in technical 
cooperation or commercial agreements.
Italy Request
Tracing and Localization 
System for People and Goods
in Hospitals and Healthcare 
Institutions (10 PT 65BN 3G4H)
A Portuguese SME has developed a tracing and localization system that can
be used in healthcare institutions to locate people and goods. This technology
improves the access in all the restricted areas of the institution specially in
the pediatric and obstetrics and psychiatric wings. 
Portugal Offer
Innovative technologies for the
obstetrics gynaecology and
fertility market (Ref: 09 NL
60AH 3FK7)
A Dutch company is specialized in valorization and commercialization of 
pharmaceutical products in the field of obstetrics gynaecology and fertility.
The main expertise is focussed on testing, implementation and product 
development. For implementation and the review of new technologies the 
company makes use of a broad network of gynaecologists in the Netherlands. 
The 
Netherlands
Request
New radiation device for 
urinal-genital passage 
disinfection (10 ES 23D1 3G62)
A Spanish technological based company created by a multidisciplinary team
has developed a new ultraviolet device to avoid urinary tract infection (UTI). It
allows new ways of sterilizing with at least one ultraviolet lamp and ozone
transmitter radiating with a removable device from the exterior to the
catheter and conducting the radiation from the catheter to the bladder
and/or to the drainage bag. 
Spain Offer
Tool for the profiling of small
RNAs (09 DE 1169 3FS5)
A German research institute with a research priority in epigenetics intends to
develop a kit to enrich small RNAs from different samples (human, animal,
plant). The institute is looking for a private partner who is interested in 
co-developing and marketing the kit. 
Germany Request
Behavioral and physiological
testing studies on small mam-
mals for pharmacological and
toxicological studies (10 ES
27F3 3G9T)
An Andalusian research group (Spain) has developed two simultaneous types
of testing in small mammals, the physiological (which measure the internal 
dynamics of the nervous system) and behavioral (measuring behavior viewed
from the outside. The institute seeks to transfer the technology through 
entering into license agreements.
Spain Offer
DNA or RNA based molecular
diagnostic technologies that
provide quantitative analysis
(09 GB 48P9 3FTX)
A small British company is looking for technologies that provide quantitative
analysis of biological materials in water or soil samples. The company currently
uses ‘qPCR’ techniques and seeks contact with organisations using either this
technology or alternatives, especially those with higher throughput. 
UK Request
Tracking of enhancer sub-
stances and its use in the cog-
nitive abilities of healthy or
deficient individuals (10 ES
27F3 3G8C)
An Andalusian research group (Spain) has developed a sophisticated 
technology to detect substances that enhance cognitive abilities in young
healthy rodents and rodent with models of neurodegenerative diseases. The
institute seeks to transfer the technology through entering into license
agreements.
Spain Offer
Would you like to contribute an article?
If you have an idea for an article or would like to include an event listing in the next EMT SIG
newsletter, contact Natalie at n.tamiollo@LTNetwork.org. Or if you’re involved in an event you
would like fellow members to know about, email Natalie and we’ll include it on our website, which
is updated weekly with the latest news and events, in the UK and internationally.
Visit www.LTNetwork.org/sig/emt
